Position in HLN
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$1,563,297
-$327,441 QoQ
Shares Held
167,556
-11.3% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#124
of 639 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026FIRST TRUST ADVISORS LP holds $670,557,120 across 30 Drug Manufacturers - Specialty & Generic names. HLN ranks #21 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
923,125 | $155,583,487 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
249,056 | $134,946,012 | |
| 3 | ALKS |
Alkermes plc.
|
2,421,016 | $126,861,238 | |
| 4 | ZTS |
Zoetis Inc.
|
1,435,652 | $103,165,952 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
2,114,912 | $33,902,039 | |
| 6 | LQDA |
Liquidia Corp
|
301,432 | $24,033,173 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,120,469 | $11,204,690 | |
| 8 | AMRX |
Amneal Pharmaceuticals, Inc.
|
614,206 | $10,631,905 |
All Filings in HLN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,563,297 | 167,556 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $1,890,738 | 188,885 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,905,947 | 188,521 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,632,611 | 182,008 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,543,398 | 148,833 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $1,356,664 | 131,843 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $516,848 | 54,177 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||